menu
    • menu
    [{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"KT809","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Kate Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"KT430","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Kate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kate Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Kate Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"2","companyTruncated":"Kate Therapeutics \/ Westlake Village BioPartners"}]

    Find Clinical Drug Pipeline Developments & Deals by Kate Therapeutics

    Menu

    Kate Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kate Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kate Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KT809

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis Acquires Kate Therapeutics in $1.1B Deal

                            Details : The acquisition of Kate enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation by including preclinical candidates KT809 for DMD, FSHD, and DM1.

                            Product Name : KT809

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : KT809

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kate Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kate Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KT430

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

                            Details : Astellas will receive license to develop, manufacture and commercialize KT430, a preclinical next-generation investigational AAV-based gene therapy that delivers a functional copy of the MTM1 gene via a novel MyoAAV capsid to treat X-linked myotubular my...

                            Product Name : KT430

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 06, 2023

                            Lead Product(s) : KT430

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kate Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kate Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Westlake Village BioPartners

                            Deal Size : $51.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kate Therapeutics Debuts with $51 Million Series A to Develop Next-generation Genetic Medicines to Treat Muscl...

                            Details : The proceeds will support the advancement of KateTx’s next generation AAV-based gene therapies for muscle and heart disease programs, including myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy, which are the leading causes of adult-...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Westlake Village BioPartners

                            Deal Size : $51.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth